Skip to main content

Table 1 Clinical and demographic characteristics of the Charité cohort

From: Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients

  dSSc lSSc SScSS Overlap UCTD All
Number 96 113 4 51 16 280
Age in yearsa 54.5 (14.7) 63.0 (11.2) 52.5 (12.9) 51 (13.2) 55.5 (10.6) 58.0 (13.3)
Duration of RP in yearsa 5 (10.2) 9.5 (12.6) 12 (21.3) 7 (8.6) 8 (9.6) 7.5 (11.3)
Duration of disease in yearsa 5 (7.7) 8 (7.0) 3.5 (6.8) 7 (7.6) 5 (10.9) 7 (7.6)
Females/males 79/17 105/8 2/2 41/10 16/0 243/37
mRSSa 11.0 (9.61) 4.0 (4.3) 1.0 (1.1) 3.0 (6.9) 0.0 (1.1) 5.0 (8.0)
Digital ulcersb 52 (54.2) 38 (33.6) 2 (50) 18 (35.2) 2 (12.5) 112 (40.0)
Lung fibrosisb 57 (59.4) 16 (14.2) 3 (75) 20 (39.2) 2 (12.5) 98 (35.0)
DLCO-SBa, % 65.3 (21.9) 78.9 (17.5) 51.1(12.8) 71.2 (21.7) 80.0 (17.1) 72.4 (20.5)
Mean FVCa, % 82.1 (18.9) 97.4 (15.2) 95.5 (30.7) 86.5 (20.5) 95.2 (18.0) 91.6 (19.0)
Contracturesb 78 (81.3) 62 (54.9) 2 (50) 27 (52.9) 3 (18.8) 172 (61.4)
PAHb 22 (22.9) 22 (19.5) 2 (50) 13(25.7) 1 (6.3) 60 (21.4)
Renal involvementb 17 (17.7) 22 (19.5) 1 (25) 14 (27.5) 2 (12.5) 56 (20.0)
Renal crisisb 10 (10.4) 3 (2.7)
n = 112
1 (25) 1 (2.0) 1 (6.3) 16 (5.7)
n = 279
Cardiac involvementb 47 (49.0) 35 (31.0) 3 (75) 25 (49) 4 (25) 117 (40.7)
Skin involvementb 94 (98.9) 105 (92.9) 3 (75) 39 (76.5) 7 (43.8) 248 (88.9)
RPb 95 (99) 110 (97.3) 4 (100) 50 (98) 13 (81.3) 272 (97.1)
  1. aValues displayed are medians (standard deviations). bValues displayed are numbers of patients (percentages). DLCO-SB, predicted diffusion capacity of a single breath; dSSc, diffuse systemic sclerosis; FVC, forced vital capacity; lSSc, limited systemic sclerosis; mRSS, modified Rodnan skin score; PAH, pulmonary arterial hypertension; RP, Raynaud phenomenon; SScSS, systemic sclerosis sine scleroderma; UCTD, undifferentiated connective tissue disease.